The consolidated earnings forecast for the second quarter of the fiscal year ending March 2027 (April 1, 2026 to September 30, 2026) has been revised upward. Revenue is revised up to 15,836 million yen from the previous forecast, operating income to 424 million yen, ordinary income to 520 million yen, and net income attributable to owners of the parent to 351 million yen. Increases of 2,296 million yen, 215 million yen, 216 million yen, and 146 million yen respectively. Prior-year results included revenue of 13,363 million yen, etc. The reason for the revision is favorable performance in the chemical business and contributions from price realization. The full-year outlook is still under review and will be disclosed at the results announcement on November 11.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"3537","jir_company_name":"\u662d\u6804\u85ac\u54c1\u682a\u5f0f\u4f1a\u793e\u4f1a\u793e\u540d\u306f\u8cc7\u6599\u4e2d\u306b\u6b63\u5f0f\u540d\u79f0\u3068\u3057\u3066\u8a18\u8f09\u3055\u308c\u3066\u3044\u308b\u304c\u3001\u73fe\u72b6\u306e\u30c6\u30ad\u30b9\u30c8\u306b\u306f\u6b63\u5f0f\u540d\u79f0\u3092\u4e00\u5b57\u4e00\u53e5\u7279\u5b9a\u3067\u304d\u308b\u660e\u78ba\u306a\u8868\u8a18\u304c\u306a\u3044\u305f\u3081\u3001\u4e0d\u660e\u3068\u3057\u307e\u3059\u3002","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-18","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/3537-20260918-01.pdf","jir_short_summary":"The consolidated earnings forecast for the second quarter of the fiscal year ending March 2027 (April 1, 2026 to September 30, 2026) has been revised upward. Revenue is revised up to 15,836 million yen from the previous forecast, operating income to 424 million yen, ordinary income to 520 million yen, and net income attributable to owners of the parent to 351 million yen. Increases of 2,296 million yen, 215 million yen, 216 million yen, and 146 million yen respectively. Prior-year results included revenue of 13,363 million yen, etc. The reason for the revision is favorable performance in the chemical business and contributions from price realization. The full-year outlook is still under review and will be disclosed at the results announcement on November 11.","jir_summary":"### Overview of Results\nThe chemical business performed well, supported by increased orders from major domestic customers and high crude oil price levels, resulting in higher revenue and profits. In particular, price realization contributed, and revenue is expected to exceed the previous forecast. The full-year consolidated earnings forecast is still under review and will be disclosed at the November 11 results announcement.\n\n### Outlook and Considerations\nThe full-year plan will be announced at the results presentation, and as of the time of this release, the full-year outlook figure has not been finalized. External factors such as exchange rates, trends in raw material prices, and ongoing demand in the chemical business may affect full-year performance.","jir_financial_highlights":"Revenue: 15,836 (YoY from previous forecast +2,296)\nOperating income: 424 (YoY from previous forecast +215)\nOrdinary income: 520 (YoY from previous forecast +216)\nNet income attributable to owners of the parent: 351 (YoY from previous forecast +146)\nEarnings per share: 102 yen 53 sen (YoY from previous forecast unknown)","jir_category":"","jir_hashtags":"#ShoeiPharmaceuticals, #EarningsRevision, #FullYearOutlookUndecided","jir_key_figures":"Revenue: 15,836 million yen\nOperating income: 424 million yen\nOrdinary income: 520 million yen\nNet income attributable to owners of the parent: 351 million yen\nEarnings per share: 102 yen 53 sen","jir_meta_title":"Shoei Pharmaceuticals | Revision of Earnings Forecast for Second Quarter of FY2027: Revenue 15,836 million yen, Operating Income 424 million yen","jir_meta_description":"Shoei Pharmaceuticals revises its consolidated earnings forecast for the second quarter of FY2027. Revenue increased from the prior estimate, and operating income, ordinary income, and net income were revised upward. The full-year outlook will be disclosed at the November 11 results announcement. Contributions from raw material trends and price realization.","jir_og_title":"Shoei Pharmaceuticals | Revision of FY2027 Q2 Earnings Forecast","jir_og_description":"Shoei Pharmaceuticals raises its second-quarter earnings forecast for FY2027. Benefiting from favorable chemical business conditions and price realization. Full-year outlook to be announced at the November 11 results briefing.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59899,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-115289","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n